跳至主要内容
临床试验/NCT05371795
NCT05371795Unknown不适用

Research Study: Tattooing of Skin Landmarks in Radiotherapy: Comparison Between the System Traditional and Comfort Marker 2.0® (COMFORTATTOO)

Instituto Portugues de Oncologia, Francisco Gentil, Porto2 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2021年10月18日最近更新:
适应症

试验速览

阶段
不适用
发起方
入组人数
100
试验地点
2
主要终点
Patients' comfort

研究概览

简要总结

Comparison on radiotherapy skin set-up markings with lancets versus Comfort Marker 2.0®

详细描述

A Prospective, unicentric, randomized, controlled, parallel, double-blinded, cohort study comparing radiotherapy skin set-up markings with lancets versus electric marking device (Comfort Marker 2.0® by CIVCO®)

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Other
盲法
Double (Participant, Care Provider)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age at least 18 years old.
  • Patients referred to our department to receive external beam radiation therapy.
  • Eastern Cooperative Oncology Group performance status of 0 to
  • Estimated fractionating schedule of at least 13 once-daily fractions.
  • Written informed consent.

排除标准

  • Patients requiring either immobilisation thermoplastic masks (for head or head and shoulders) or vacuum cushion.

结局指标

主要结局

Patients' comfort

时间窗: Day 1

Comfort is verbally assessed on the 11-point numeric pain scale. As more than one reference point is tattooed, the patients are asked to give an overall score to the procedure.

Effectiveness

时间窗: up to 7 weeks

Effectiveness is assessed by the RTT team that delivered the daily fractions. Skin markings are individually evaluated at several periods, specifically at the first fraction, then every 5 fractions, and one last time in the last fraction of RT. These evaluations are scored on a 4-point graded scale (corresponding to bad, reasonable, good, and excellent).

次要结局

  • RTTs' satisfaction(Day 1)
  • Cosmesis(one of the last three days of irradiation)

研究者

发起方
Instituto Portugues de Oncologia, Francisco Gentil, Porto
申办方类型
Other
责任方
Principal Investigator
主要研究者

André Miranda Pires

Principal Investigator

Instituto Portugues de Oncologia, Francisco Gentil, Porto

研究点 (2)

Loading locations...

相似试验